Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11381473 | 0.96 | KDM4E (0.66) | KDM4EL3MBTL1AOC3ALDH1A1ADRB2 | |
| SCHEMBL21896763 | 0.96 | KDM4E (0.66) | KDM4EL3MBTL1AOC3ALDH1A1ADRB2 | |
| SCHEMBL20689722 | 0.86 | KDM4E (0.73) | KDM4EL3MBTL1AOC3ALDH1A1ADRB2 | |
| SCHEMBL7532494 | 0.83 | KDM4E (1.00) | KDM4EL3MBTL1AOC3ALDH1A1ADRB2 | |
| SCHEMBL4408535 | 0.83 | KDM4E (1.00) | KDM4EL3MBTL1AOC3ALDH1A1ADRB2 | |
| SCHEMBL5093264 | 0.83 | KDM4E (0.52) | KDM4EL3MBTL1AOC3ALDH1A1BCAT2 | |
| SCHEMBL6320068 | 0.82 | KDM4E (0.73) | KDM4EL3MBTL1AOC3ALDH1A1ADRB2 | |
| SCHEMBL1626455 | 0.82 | KDM4E (0.73) | KDM4EL3MBTL1AOC3ALDH1A1ADRB2 | |
| SCHEMBL9768636 | 0.82 | GRIN1 (0.70) | KDM4EL3MBTL1KMT2AGRIN1GRIN2A | |
| SCHEMBL11747290 | 0.81 | AOC3 (0.46) | KDM4EL3MBTL1AOC3ALDH1A1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981958-B2 | Oxazolidines derived from polyalkyl or polyalkenyl n-hydroxyalkyl succinimides, obtainment process and use | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2018-05-29 | — | — | US | disclosed |
| US-9221803-B2 | Asphaltene-dispersing/inhibiting additive based on oxazolidines derived from polyalkyl or polyalkenyl N-hydroxyalkyl succinimides | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2015-12-29 | — | — | US | disclosed |
| US-20110162558-A1 | Formulations comprising an asphaltene-dispersing/inhibiting additive based on oxazolidines derived from polyalkyl or polyalkenyl N-hydroxyalkyl succinimides | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2011-07-07 | — | — | US | disclosed |
| US-20100107478-A1 | Oxazolidines derived from polyalkyl or polyalkenyl n-hydroxyalkyl succinimides, obtainment process and use | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2010-05-06 | — | — | US | disclosed |
| US-4315846-A | FUNGICIDES | TOKYO ORGANIC CHEMICAL INDUSTRIES, LTD. (JP) | 1982-02-16 | — | — | US | disclosed |
| EP-0037861-A1 | Salts of alkylenebisdithiocarbamic acid derivatives, processes for their preparation, fungicidal compositions containing them and methods of combating fungi | TOKYO ORGANIC CHEMICAL INDUSTRIES, LTD. (JP) | 1981-10-21 | — | — | EP | disclosed |
| US-4117157-A | TREATMENT OF CARDIOVASCULAR DISORDERS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-09-26 | — | — | US | disclosed |
| US-4005212-A | ANTIDEPRESSANT, ANOREXIGENIC, PSYCHOENERGIZING, 2-PHENYL-2,3,5,6-TETRAHYDROIMIDAZO(2,1-B)THIAZOLE | RHONE-POULENC S.A. (FR) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100107478-A1 | Oxazolidines derived from polyalkyl or polyalkenyl n-hydroxyalkyl succinimides, obtainment process and use | HRH4, OGDH, HRH3 | KDM4E 338/4885L3MBTL1 2841/4885AOC3 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.